The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1737
September 15, 2025
View Complete Issue         Table of Contents 2019 
Inclisiran (Leqvio) Monotherapy for LDL-Cholesterol Reduction
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Inclisiran (Leqvio) Monotherapy for LDL-Cholesterol Reduction
September 15, 2025 (Issue: 1737)
Inclisiran (Leqvio – Novartis), a subcutaneously injected small interfering RNA (siRNA) that decreases LDL-cholesterol (LDL-C) levels by reducing synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9), has been approved by the FDA...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Inclisiran (Leqvio) Monotherapy for LDL-Cholesterol Reduction
Article code: 1737c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.